Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
Pharmaceutics|March 29, 2023
Lentiviral Vectors as a Vaccine Platform against Infectious DiseasesKirill Nemirov, Maryline Bourgine, François Anna, et al.Frontiers in Immunology|September 14, 2020
HLA-G Neo-Expression on TumorsMaria Loustau, François Anna, Raphaelle Dréan, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|June 3, 2020
A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika VirusMin Wen Ku, François Anna, Philippe Souque, et al.Frontiers in Immunology|January 28, 2021
Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DCChing-Lien Wu, Julien Caumartin, Giada Amodio, et al.NPJ Vaccines|July 4, 2025
Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneityBenjamin Vesin, Ingrid Fert, Amandine Noirat, et al.Journal for Immunotherapy of Cancer|March 19, 2021
First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-GFrançois Anna, Elodie Bole-Richard, Joel LeMaoult, et al.NPJ Vaccines|June 10, 2024
T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vectorIngrid Fert, Laëtitia Douguet, Benjamin Vesin, et al.Cell Reports|July 29, 2022
A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4+ T cell immunityJodie Lopez, François Anna, Pierre Authié, et al.EMBO Molecular Medicine|September 7, 2023
Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccineLaëtitia Douguet, Ingrid Fert, Jodie Lopez, et al.The Lancet. Public Health|February 8, 2021
Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional studyThomas Roederer, Bastien Mollo, Charline Vincent, et al.Pageof 3